Cargando…

The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy

Fosfomycin in intravenous (IV) formulation has re-emerged as a valuable tool in the treatment of multi-drug resistant (MDR) and extensively drug-resistant (XDR) infections because of its broad spectrum of antibacterial action and pharmacokinetic characteristics. This retrospective study aimed to eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Anastasia, Antonio, Bonura, Silvia, Rubino, Raffaella, Giammanco, Giovanni Maurizio, Miccichè, Irene, Di Pace, Maria Rita, Colomba, Claudia, Cascio, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295113/
https://www.ncbi.nlm.nih.gov/pubmed/37370290
http://dx.doi.org/10.3390/antibiotics12060971
_version_ 1785063343127527424
author Anastasia, Antonio
Bonura, Silvia
Rubino, Raffaella
Giammanco, Giovanni Maurizio
Miccichè, Irene
Di Pace, Maria Rita
Colomba, Claudia
Cascio, Antonio
author_facet Anastasia, Antonio
Bonura, Silvia
Rubino, Raffaella
Giammanco, Giovanni Maurizio
Miccichè, Irene
Di Pace, Maria Rita
Colomba, Claudia
Cascio, Antonio
author_sort Anastasia, Antonio
collection PubMed
description Fosfomycin in intravenous (IV) formulation has re-emerged as a valuable tool in the treatment of multi-drug resistant (MDR) and extensively drug-resistant (XDR) infections because of its broad spectrum of antibacterial action and pharmacokinetic characteristics. This retrospective study aimed to evaluate how fosfomycin was used in patients admitted to the Polyclinic of Palermo between January 2017 and July 2022. Clinical indications, therapeutic associations, clinical outcomes, and any side effects were analyzed. Intravenous fosfomycin was used in 343 patients, 63% male, with a mean age of 68 years (range 15–95). Urinary tract infections (UTIs) and hospital-acquired pneumonia (HAP) were the main indications for treatment (19% and 18% of the total cases, respectively), followed by skin and soft tissue infections and sepsis. IV fosfomycin was administered in combination with other antibacterial agents, the most common of which were ceftazidime/avibactam (35%), meropenem (17%), and colistin (14%). Nineteen patients received it as monotherapy for UTIs. About 66% had resolution of the infectious process with clinical remission (cure or discharge). Electrolyte disturbances occurred in 2.6% and gastrointestinal symptoms occurred in 2.9%. The data showed that IV fosfomycin is a safe and effective therapeutic option in the treatment of infections with multidrug-resistant microorganisms.
format Online
Article
Text
id pubmed-10295113
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102951132023-06-28 The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy Anastasia, Antonio Bonura, Silvia Rubino, Raffaella Giammanco, Giovanni Maurizio Miccichè, Irene Di Pace, Maria Rita Colomba, Claudia Cascio, Antonio Antibiotics (Basel) Article Fosfomycin in intravenous (IV) formulation has re-emerged as a valuable tool in the treatment of multi-drug resistant (MDR) and extensively drug-resistant (XDR) infections because of its broad spectrum of antibacterial action and pharmacokinetic characteristics. This retrospective study aimed to evaluate how fosfomycin was used in patients admitted to the Polyclinic of Palermo between January 2017 and July 2022. Clinical indications, therapeutic associations, clinical outcomes, and any side effects were analyzed. Intravenous fosfomycin was used in 343 patients, 63% male, with a mean age of 68 years (range 15–95). Urinary tract infections (UTIs) and hospital-acquired pneumonia (HAP) were the main indications for treatment (19% and 18% of the total cases, respectively), followed by skin and soft tissue infections and sepsis. IV fosfomycin was administered in combination with other antibacterial agents, the most common of which were ceftazidime/avibactam (35%), meropenem (17%), and colistin (14%). Nineteen patients received it as monotherapy for UTIs. About 66% had resolution of the infectious process with clinical remission (cure or discharge). Electrolyte disturbances occurred in 2.6% and gastrointestinal symptoms occurred in 2.9%. The data showed that IV fosfomycin is a safe and effective therapeutic option in the treatment of infections with multidrug-resistant microorganisms. MDPI 2023-05-27 /pmc/articles/PMC10295113/ /pubmed/37370290 http://dx.doi.org/10.3390/antibiotics12060971 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Anastasia, Antonio
Bonura, Silvia
Rubino, Raffaella
Giammanco, Giovanni Maurizio
Miccichè, Irene
Di Pace, Maria Rita
Colomba, Claudia
Cascio, Antonio
The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy
title The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy
title_full The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy
title_fullStr The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy
title_full_unstemmed The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy
title_short The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy
title_sort use of intravenous fosfomycin in clinical practice: a 5-year retrospective study in a tertiary hospital in italy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295113/
https://www.ncbi.nlm.nih.gov/pubmed/37370290
http://dx.doi.org/10.3390/antibiotics12060971
work_keys_str_mv AT anastasiaantonio theuseofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly
AT bonurasilvia theuseofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly
AT rubinoraffaella theuseofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly
AT giammancogiovannimaurizio theuseofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly
AT miccicheirene theuseofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly
AT dipacemariarita theuseofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly
AT colombaclaudia theuseofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly
AT cascioantonio theuseofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly
AT anastasiaantonio useofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly
AT bonurasilvia useofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly
AT rubinoraffaella useofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly
AT giammancogiovannimaurizio useofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly
AT miccicheirene useofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly
AT dipacemariarita useofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly
AT colombaclaudia useofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly
AT cascioantonio useofintravenousfosfomycininclinicalpracticea5yearretrospectivestudyinatertiaryhospitalinitaly